⌕
Ionis Pharmaceuticals · IONS · Nasdaq
Tenet 27 · Weak
Compare
$29.06+6.41%At closeTenet 27 · Weak
$29.06+1.75 (+6.41%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Ionis Pharmaceuticals (IONS) Earnings Forecast

Analysts expect Ionis Pharmaceuticals (IONS) to lose $3.47 a share in FY26, the average of 7 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$−3.47
7 analysts
FY27 consensus EPS
$−3.01
11 analysts · low $−4.42, high $−1.90
EPS revisions, 30 days
+3.6%
$−3.60 to $−3.47
Disagreement, FY26
$0.10
wide, $−3.54 to $−3.43

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Ionis Pharmaceuticals to earn $3.39 a share in FY30; 11 analysts publish an estimate for FY30.

Forward P/E · FY26E
—
$29.06 (as of close, Nov 13, 2026) ÷ $−3.47 consensus EPS
Coverage · FY26
7 · 18
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $−3.47, a loss that narrowed 3.3% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−70.1%−27.7%+14.7%FY26 +3.3%FY27 −58.9%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 6
FY267 analysts▲ +3.6%$−3.60 to $−3.47▲ +3.3%$−3.59 to $−3.47▲ +3.7%$−3.61 to $−3.47
FY2711 analysts▼ −43.2%$−2.10 to $−3.01▼ −58.9%$−1.89 to $−3.01▼ −164.3%$−1.14 to $−3.01
Sep '265 analysts▼ −1.8%$−1.21 to $−1.23▼ −1.4%$−1.21 to $−1.23▼ −14.5%$−1.07 to $−1.23
Dec '264 analysts▼ −25.2%$−1.08 to $−1.35▼ −27.5%$−1.06 to $−1.35▼ −27.5%$−1.06 to $−1.35

Contributors at both ends of the window: FY26 10 and 7. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY28 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY29
$0.4B
7 analysts · low $0.3B, high $0.5B · thin coverage
Multiple · five-year average P/E
29.9×
Average of the fiscal-year P/Es, FY18 to FY19.
×
Receipt · IONS · FY29Nov 13, 2026
Implied, a share
$73

Range on the low and high estimate: $3 to $3.

$3 low$3 high
0.4B × 29.9, to the dollar
Drag the multipleShaded: where Ionis Pharmaceuticals' P/E sat at each fiscal year end, FY18 to FY19. Each dot is one year.
25×30×35×
5-yr avg 29.9×10-yr median 29.9×$73 a share

Each point on the line is a multiple, and the flag is the price it implies for FY29. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.Show the multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY18 to FY19 · over 2 fiscal years, with 1 year of near-zero earnings left out. The mark is the median of the last 2.
26.5× low33.3× high
29.9× median
We hold no trailing multiple for this company today, so nothing marks today on the track.

How much do analysts disagree?

For FY30, estimates run from $2.41 to $4.64 around an average of $3.39, drawn by 11 analysts.

FY26E7 analysts
$−3.54 to $−3.43 · $0.10 wide
FY27E11 analysts
$−4.42 to $−1.90 · $2.52 wide
FY28E14 analysts
$−3.34 to $1.94 · $5.28 wide
FY29E7 analysts
$0.89 to $1.72 · $0.83 wide
FY30E11 analysts
$2.41 to $4.64 · $2.23 wide

The dashed line is FY25 filed $−2.38, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Ionis Pharmaceuticals to lose $1.35 a share in the December quarter, the average of 4 estimates. Results are expected by Feb 16, 2027.

0
$−1.35
$−1.35high $−1.33
low $−1.38
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 4 analysts
Expected report
Feb 16, 2027
Expected by Feb 16. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$178.9M
7 analysts, 118.3 to 240.8 in $M · 203.3 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. For the March quarter, analysts expect a loss of $1.08 a share.

Does Ionis Pharmaceuticals usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Ionis Pharmaceuticals begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported. The next report is expected by Feb 16, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '23left out
Mar '24left out
Jun '24left out
Sep '24left out
Dec '24left out
Mar '25left out
Jun '25left out
Sep '25left out
Dec '25left out
Mar '26left out
Jun '26left out
Sep '26left out
reportsFeb 16
Dec '26
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Ionis Pharmaceuticals on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 25.0% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

7 analysts publish an EPS estimate for FY26 and 18 publish revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
187
FY26E
1911
FY27E
1814
FY28E
107
FY29E
911
FY30E
The FY26 panel held 10 analysts when our record of it began on Jul 6, 2026 and holds 7 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
0.41.93.3historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 18 revenue estimates for FY26, 9 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−4.960.025.00historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 7 EPS estimates for FY26, 11 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.9—−2.38————as filedn/m
FY26E0.90.9 to 1.0▼2.6%a−3.47−3.54 to −3.43n/ca−0.4−0.60.1618 · 7—
FY27E1.10.8 to 1.4▲25.0%−3.01−4.42 to −1.90n/cb−0.4−0.50.1719 · 11—
FY28E1.61.1 to 2.1▲36.8%−0.84−3.34 to 1.94—0.20.1−0.1018 · 14—
FY29E2.01.6 to 2.6n/cb1.250.89 to 1.72n/cb0.40.20.1610 · 723.2×
FY30E2.52.0 to 3.2▲24.8%3.392.41 to 4.64n/cb0.80.50.169 · 118.6×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 7 EPS estimates for FY26, 18 for revenue. Not investment advice.

What do analysts expect Ionis Pharmaceuticals to earn in FY26?

Analysts expect Ionis Pharmaceuticals to lose $3.47 a share in FY26, the average of 7 estimates as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.